Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity-Reference-Cited by-同舟云学术

Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity

Published:2023-02-19 Issue:4 Volume:12 Page:659
ISSN:2073-4409
Container-title:Cells
language:en
Short-container-title:Cells

Author:

Kciuk Mateusz¹²^ORCID,Gielecińska Adrianna¹²^ORCID,Mujwar Somdutt³^ORCID,Kołat Damian⁴^ORCID,Kałuzińska-Kołat Żaneta⁴^ORCID,Celik Ismail⁵^ORCID,Kontek Renata¹^ORCID

Affiliation:

1. Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland

2. Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, Poland

3. Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India

4. Department of Experimental Surgery, Faculty of Medicine, Medical University of Lodz, 90-136 Lodz, Poland

5. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey

Abstract

Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX’s action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species (ROS) production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role. This review aims to collect information on the anticancer mechanisms of DOX as well as its influence on anti-tumor immune response, providing a rationale behind the importance of DOX in modern cancer therapy.

Publisher

MDPI AG

Subject

General Medicine

Link

https://www.mdpi.com/2073-4409/12/4/659/pdf

Reference278 articles.

1. Co-Treatment by Docetaxel and Vinblastine Breaks down P-Glycoprotein Mediated Chemo-Resistance;Mohseni;Iran. J. Basic Med. Sci.,2016

2. Improvement of Conventional Anti-Cancer Drugs as New Tools against Multidrug Resistant Tumors;Dallavalle;Drug Resist. Updat.,2020

3. Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int. J. Mol. Sci., 21.

4. Doxorubicin: The Good, the Bad and the Ugly Effect;Carvalho;Curr. Med. Chem.,2009

5. Doxorubicin-Induced Cardiotoxicity: An Update on the Molecular Mechanism and Novel Therapeutic Strategies for Effective Management;Rawat;Biomed. Pharmacother.,2021

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sulfiredoxin 1 ameliorates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via the Sirt1/NLRP3 pathway;International Immunopharmacology;2024-11

2. Functional exosomes modified with chitosan effectively alleviate anthracycline-induced cardiotoxicity;International Journal of Biological Macromolecules;2024-10

3. Doxorubicin-galactomannan nanoconjugates for potential cancer treatment;Carbohydrate Polymers;2024-10

4. Long noncoding RNAs as potential targets for overcoming chemoresistance in upper gastrointestinal cancers;Biomedicine & Pharmacotherapy;2024-10

5. Dual-Action Therapeutics: DNA Alkylation and Antimicrobial Peptides for Cancer Therapy;Cancers;2024-09-10